Stocks and Investing Stocks and Investing
Wed, November 16, 2022

Graig Suvannavejh Maintained (BTAI) at Strong Buy with Decreased Target to $18 on, Nov 16th, 2022


Published on 2024-10-28 00:12:12 - WOPRAI, Graig Suvannavejh
  Print publication without navigation


Graig Suvannavejh of Mizuho, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $19 to $18 on, Nov 16th, 2022.

Graig has made no other calls on BTAI in the last 4 months.



There are 3 other peers that have a rating on BTAI. Out of the 3 peers that are also analyzing BTAI, 0 agree with Graig's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Graig


  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $76 on, Friday, November 11th, 2022
  • Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $25 on, Friday, November 11th, 2022
  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $85 on, Wednesday, August 24th, 2022

Contributing Sources